Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status.

被引：0
|
作者：
Kharenko, Olesya A. [1 ]
Patel, Reena [1 ]
Calosing, Cyrus [1 ]
机构：
[1] Zenith Epigenet, Calgary, AB, Canada
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1129
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    María Jimena Rodriguez
    María Cecilia Perrone
    Marina Riggio
    Marta Palafox
    Valeria Salinas
    Andrés Elia
    Natali Daiana Salgueiro
    Andrea Eugenia Werbach
    María Paula Marks
    Marcelo A. Kauffman
    Luciano Vellón
    Violeta Serra
    Virginia Novaro
    Scientific Reports, 13
  • [22] Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
    Petroni, Giulia
    Buque, Aitziber
    Yamazaki, Takahiro
    Bloy, Norma
    Di Liberto, Maurizio
    Chen-Kiang, Selina
    Formenti, Silvia C.
    Galluzzi, Lorenzo
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1855 - 1863
  • [23] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    Rodriguez, Maria Jimena
    Perrone, Maria Cecilia
    Riggio, Marina
    Palafox, Marta
    Salinas, Valeria
    Elia, Andres
    Salgueiro, Natali Daiana
    Werbach, Andrea Eugenia
    Marks, Maria Paula
    Kauffman, Marcelo A.
    Vellon, Luciano
    Serra, Violeta
    Novaro, Virginia
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [24] Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors
    Cruz, Marcelo R.
    Limentani, Kimberly
    Taxter, Timothy
    Santa-Maria, Cesar A.
    Behdad, Amir
    Gradishar, William J.
    Nagy, Rebecca J.
    Cristofanilli, Massimo
    CANCER RESEARCH, 2018, 78 (04)
  • [25] CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S205 - S209
  • [26] Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
    Scheidemann, Erin R.
    Shajahan-Haq, Ayesha N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [27] Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
    Schedin, Troy B.
    Borges, Virginia F.
    Shagisultanova, Elena
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2018, 2018
  • [28] Proteogenomic characterization of CDK4/6 inhibitor-resistant ER plus breast cancer
    Chen, Christopher T.
    Leshchiner, Ignaty
    Martin, Liz
    Kane, Harry
    Rhrissorrakrai, Kahn
    Utro, Filippo
    Levovitz, Chaya
    Gillette, Michael
    Satpathy, Shankha
    Pinto, Christopher
    McLoughlin, Daniel
    Allen, Read
    Danysh, Brian P.
    Slowik, Kara
    Jacobs, Raquel A.
    Carr, Steven
    Parida, Laxmi
    Getz, Gad
    Juric, Dejan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [29] Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Shia, A.
    Wilkes, E.
    Casado-Izguierdo, P.
    Cutillas, P.
    Schmid, P.
    CANCER RESEARCH, 2016, 76
  • [30] New Therapeutic Approach for metastatic Breast Cancer CDK4/6-Inhibitors as an Enhancer for endocrine Therapy
    Bischoff, Angelika
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (11)
12345